Aeonbiopharma
NYSE: AEON1 known investors
AEON Biopharma develops ABP-450 (prabotulinumtoxinA), a branded biosimilar to BOTOX®, targeting therapeutic indications for neuromuscular conditions. The company uses the FDA's biosimilar pathway to expand access to therapeutic botulinum toxin treatments for patients, providers, and payers.
Investors · 1
Competitors · 3
by search overlapSimply Wall St7 shared keywordsSimply Wall St is a stock analysis platform that provides portfolio insights, stock discovery tools, and market alerts for individual investors. The service offers institutional-grade financial data visualization and analysis across 120,000 global stocks.
TradingView7 shared keywordsTradingView is a charting platform and social network used by over 100 million traders and investors worldwide to analyze and trade across global financial markets. The platform provides tools for technical analysis, market data, and community collaboration for retail and institutional traders.
StockTwits6 shared keywordsStocktwits operates an online community platform where investors and traders share ideas, analysis, and trade discussions organized around stock tickers. The page presented is its community guidelines rather than a product description.
Companies competing with Aeonbiopharma for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does Aeonbiopharma do?
- AEON Biopharma develops ABP-450 (prabotulinumtoxinA), a branded biosimilar to BOTOX®, targeting therapeutic indications for neuromuscular conditions. The company uses the FDA's biosimilar pathway to expand access to therapeutic botulinum toxin treatments for patients, providers, and payers.
- Who are Aeonbiopharma's investors?
- Aeonbiopharma's investors include Longitude Capital.